Cefepime-Taniborbactam in Complicated Urinary Tract Infection.

Florian M WagenlehnerLeanne B GasinkPaul C McGovernGreg MoeckPatrick McLerothMaryBeth DorrAaron DaneTim Henkelnull null

Published in: The New England journal of medicine (2024)

Cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a safety profile similar to that of meropenem. (Funded by Venatorx Pharmaceuticals and others; CERTAIN-1 ClinicalTrials.gov number, NCT03840148.).

Keyphrases

urinary tract infection
liver failure
gram negative
respiratory failure
drug induced
multidrug resistant
aortic dissection
extracorporeal membrane oxygenation
replacement therapy
acute respiratory distress syndrome